Trevi Therapeutics, Inc.
NASDAQ:TRVIBiotechnology
+$0.43 today
- Market cap
- $1.93B
- Beta
- 1.05
- P/E (TTM)
- -53.6
- EPS (TTM)
- -$0.31
Volume 2.02M
Average 1.44M
TRVI Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Trevi Therapeutics, Inc.NASDAQ: TRVI
Capital Expenditures · Q3 FY2026 · quarter ended Sep 2026
Capital expenditures grows, but more slowly than its trailing trend
Q3 FY2026 capital expenditures of $25K (cash outflow) rose 108.3% year over year, behind the +1221.1% change in trailing-twelve-month capital expenditures. Sequentially, it fell 79.8% from the prior quarter. Over 3 fiscal years it compounded at -57.7% a year.
Context
- Capital expenditures grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +108.3% toward the trailing-twelve-month pace of +1221.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (12K) USD
- Year-over-year change
- +65.7%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (12K) | +65.7% |
| FY2024 | 2024-12-31 | (35K) | +74.5% |
| FY2023 | 2023-12-31 | (137K) | +13.8% |
| FY2022 | 2022-12-31 | (159K) | — |
| FY2021 | 2021-12-31 | 0 | — |
Capital Expenditures vs competitors
How TRVI compares with its peers on the latest reported figures
- Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +1221.1% is the 2nd highest of 8, against a peer median of -74.7%.
- Over three fiscal years its annual growth of -57.7% compares with a peer median of +27.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $19.91M USD | +2327.6% | — | 1.7% | |
| LTM Jun 2026 | $18.52M USD | +133.8% | +94.2% | 4.1% | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $411K USD | -74.7% | +29.4% | 2.1% |
| LTM Sep 2026 | $251K USD | +1221.1% | -57.7% | — | |
UPBUpstream Bio, Inc. | LTM Mar 2026 | $47K USD | -90.8% | +26.2% | 1.4% |
| LTM Mar 2026 | $42K USD | -82.6% | -58.1% | 0.0% | |
| LTM Mar 2026 | $0 USD | +100.0% | — | 0.0% | |
VCREVicore Pharma Holding AB | LTM Jun 2026 | SEK 0 SEK | — | — | 0.0% |
| LTM Mar 2026 | $0 USD | -100.0% | — | — | |
| Peer median (excluding TRVI) | — | -74.7% | +27.8% | 1.4% | |
Competitors are the stored peer set for TRVI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (33.94M) | (29.15M) | (29.07M) | (47.91M) | (42.76M) |
| Depreciation & Amortization | 50K | 43K | 123K | 147K | 144K |
| Deferred Income Tax | (82K) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.54M | 2.33M | 2.25M | 3.59M | 5.19M |
| Change in Working Capital | 1.51M | (1.23M) | (3.85M) | 6.83M | (3.49M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 831K | 9K | (1.05M) | 1.61M | (598K) |
| Other Working Capital | 678K | (1.24M) | (2.8M) | 5.22M | (2.89M) |
| Other Non-Cash Items | 974K | (162K) | (1.17M) | (907K) | (1.17M) |
| Operating Cash Flow | (28.95M) | (28.18M) | (31.71M) | (38.26M) | (42.09M) |
| Capital Expenditures | 0 | (159K) | (137K) | (35K) | (12K) |
| Acquisitions (Net) | 0 | (829K) | 0 | 0 | 0 |
| Purchases of Investments | 0 | (126.22M) | (9.93M) | (98.46M) | (170.66M) |
| Sales of Investments | 0 | 19M | 69.5M | 75.6M | 74.93M |
| Other Investing Activities | 0 | 829K | 0 | 1.37M | 1.64M |
| Investing Cash Flow | 0 | (107.37M) | 59.43M | (21.53M) | (94.11M) |
| Debt Repayment | (68K) | (5.83M) | (9.41M) | (126K) | 0 |
| Common Stock Issued | 21.18M | 105.41M | 1.71M | 61.15M | 120.3M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (340K) | 11.73M | (211K) | 464K | 714K |
| Financing Cash Flow | 20.78M | 111.31M | (7.91M) | 61.48M | 121.01M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (8.17M) | (24.24M) | 19.81M | 1.7M | (15.18M) |
| Free Cash Flow | (28.95M) | (28.33M) | (31.85M) | (38.29M) | (42.1M) |
Trevi Therapeutics, Inc.
NASDAQ:TRVI
Intrinsic Alpha fair value
Locked
Current Price
$13.51
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.